MK-677 (Ibutamoren) and Cannabis: Full Interaction Profile

What Is MK-677 (Ibutamoren) and How Does It Work?

MK-677 is an orally active, selective ghrelin receptor agonist that mimics the action of ghrelin at GHSR-1a receptors in the pituitary and hypothalamus. A single oral dose of 25 mg raises mean 24-hour GH secretion by approximately 97% and IGF-1 by 60-90% compared to placebo in healthy adults. It is not FDA-approved for any indication and is sold as a research compound.

Mechanism at GHSR-1a

Ghrelin, the endogenous ligand for GHSR-1a, is sometimes called the "hunger hormone." When MK-677 binds the same receptor, it reproduces two of ghrelin's core actions: stimulating pulsatile GH release and strongly increasing appetite. In a landmark 2-year randomized trial by Murphy et al. (N=65 older adults), MK-677 at 25 mg/day significantly increased fat-free mass and raised serum IGF-1 by 39.9% above baseline, though fasting blood glucose rose by a mean of 0.3 mmol/L and insulin resistance worsened in a subset of participants [1].

Metabolic Trade-offs

Because GHSR-1a signaling sits upstream of insulin secretion, MK-677 consistently produces mild insulin resistance in clinical studies. Fasting plasma insulin levels rose significantly versus placebo in the Murphy trial, and roughly 18% of participants showed clinically meaningful increases in fasting glucose [1]. This metabolic context matters when any second agent that also affects glucose homeostasis is added.

Cannabis Pharmacology Relevant to MK-677 Users

Cannabis contains over 100 identified cannabinoids, but delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) drive the most clinically relevant effects. THC acts primarily at CB1 receptors; CBD has a more complex multi-target profile that includes weak CB1 antagonism, TRPV1 agonism, and modulation of CYP450 enzymes.

THC and Appetite

CB1 receptors are densely expressed in the hypothalamic arcuate nucleus, the same region where ghrelin and MK-677 exert their orexigenic effects. A controlled crossover study (N=21) demonstrated that inhaled THC significantly increased total caloric intake by approximately 40% above baseline at a test meal, with preference shifting toward high-fat, high-carbohydrate foods [2]. The appetite pathway activated by THC overlaps anatomically and functionally with the ghrelin/GHSR-1a pathway engaged by MK-677.

CBD and CYP Enzyme Inhibition

CBD is a potent inhibitor of CYP2C9, CYP2C19, and CYP3A4 at plasma concentrations achievable with moderate doses [3]. MK-677 itself is primarily metabolized via CYP3A4. In theory, concurrent high-dose CBD use could slow MK-677 clearance, raising plasma exposure. This is speculative for typical recreational doses, but relevant for patients using pharmaceutical-grade CBD (e.g., Epidiolex at 10-20 mg/kg/day), where CYP3A4 inhibition is clinically confirmed.

Cannabis and Insulin Resistance

The relationship between cannabis and glucose metabolism is dose-dependent and somewhat paradoxical. Epidemiological data from NHANES (N=4,657) showed that current cannabis users had lower fasting insulin (by 16%) and smaller waist circumference than never-users, suggesting a possible acute insulin-sensitizing effect from intermittent use [4]. Chronic, heavy daily use tells a different story. Regular exposure to THC desensitizes CB1 receptors in adipose tissue and liver, a process associated with dyslipidemia and impaired glucose handling in animal models [5].

The Core Interaction: Appetite Amplification

Both agents independently increase appetite. Combined use likely produces additive or greater-than-additive hunger signaling. There are no RCT data on this combination, but the mechanistic case is straightforward.

Dual Orexigenic Pathways

MK-677 elevates ghrelin-mimetic signaling at GHSR-1a in the arcuate nucleus, increasing neuropeptide Y (NPY) and agouti-related peptide (AgRP) release, both potent appetite drivers. THC increases appetite through a separate but convergent CB1-dependent mechanism that also upregulates NPY in the hypothalamus [6]. Activating both pathways simultaneously removes two independent brakes on feeding behavior at once.

Practical Caloric Consequence

A user running MK-677 at 25 mg/day might experience 400-700 kcal/day of increased appetite, based on body-composition trial data. Adding cannabis could push that surplus higher. For a person trying to maximize lean mass gain, this may be intentional. For someone managing weight or insulin sensitivity, uncontrolled hyperphagia is a real risk.

The HealthRX clinical team has developed a tiered risk framework for this combination:

Tier 1 (Low concern): Occasional CBD-dominant cannabis, no metabolic comorbidities, BMI <30, fasting glucose <100 mg/dL. Monitor appetite and weight monthly.

Tier 2 (Moderate concern): Regular THC use (3-5 days/week), BMI 30-35, or pre-diabetes (fasting glucose 100-125 mg/dL). Require baseline HbA1c, quarterly glucose monitoring, and dietary logging.

Tier 3 (High concern): Daily THC use, Type 2 diabetes or HbA1c >6.5%, active cardiovascular disease, or concurrent use of high-dose pharmaceutical CBD (Epidiolex). Combination not recommended without specialist oversight.

Blood Glucose and Insulin Resistance: The Compounding Risk

This is the interaction that carries the most clinical weight. Both agents can independently worsen insulin sensitivity, and the direction of effect stacks unfavorably in high-risk users.

MK-677's Glucose Effect

In the Murphy 2-year trial, fasting glucose rose from 5.1 to 5.4 mmol/L (91.8 to 97.2 mg/dL) in the MK-677 group versus no change in placebo [1]. A separate 12-month trial in GH-deficient adults (N=30) similarly showed significant elevations in fasting insulin at 6 and 12 months, meeting criteria for insulin resistance by HOMA-IR in 23% of participants [7]. MK-677 does not appear to cause frank diabetes in previously normoglycemic individuals at 25 mg/day, but it moves the needle.

Cannabis and Glucose: The Dose-Dependency Problem

As noted above, low-to-moderate cannabis use shows insulin-sensitizing signals in cross-sectional studies [4]. Chronic heavy use reverses this. Animal data from rodent models show that sustained CB1 activation in hepatocytes increases de novo lipogenesis and impairs insulin receptor signaling [5]. Translating rodent data to humans requires caution, but the directional signal across species is consistent.

Combined Metabolic Monitoring Protocol

Users combining MK-677 with regular cannabis should obtain:

• Fasting glucose and fasting insulin at baseline
• HbA1c at baseline and every 3 months
• Fasting lipid panel (MK-677 may increase LDL in some users)
• Body weight and waist circumference monthly

A fasting glucose persistently above 100 mg/dL or HOMA-IR above 2.5 should prompt dose reduction or discontinuation of MK-677, regardless of cannabis use status.

Cardiovascular Considerations

MK-677 occasionally causes mild fluid retention (edema, reported in roughly 20% of users in clinical trials at 25 mg/day [1]), which can modestly raise blood pressure. THC acutely increases heart rate by 20-50 beats per minute in naive users and transiently raises blood pressure, though this effect attenuates with tolerance [8].

Acute Cardiac Stress

The combination of THC-driven tachycardia and MK-677-related fluid retention theoretically increases myocardial work in the short term. For healthy young adults with no cardiac history, this is unlikely to be clinically significant. For users over 40, those with existing hypertension, or anyone with a personal or family history of arrhythmia, the combination warrants a pre-use cardiovascular assessment.

Resting Heart Rate Monitoring

A simple at-home protocol: resting heart rate above 100 bpm for more than two consecutive days, or any sustained palpitations, should prompt hold on both agents and clinical evaluation. Wearable devices (Apple Watch Series 4 or later, Fitbit Charge 5 or later) have FDA 510(k) clearance for single-lead ECG recording and can flag AF episodes, which is a reasonable safety net.

Sedation and Sleep Architecture Effects

MK-677 at 25 mg/day measurably alters sleep architecture. In a controlled study (N=8 young adults, N=6 older adults), Van Coevorden et al. Showed that MK-677 increased slow-wave (stage 3/4) sleep duration and REM sleep compared to placebo [9]. This is generally considered a benefit, as slow-wave sleep is the primary period of endogenous GH secretion.

THC's Opposing Effect on Sleep

THC suppresses REM sleep. A meta-analysis of 24 controlled studies found that THC administration reduced REM sleep percentage by a mean of 3.3 percentage points versus placebo [10]. Because MK-677 works partly through slow-wave sleep enhancement to potentiate its GH-amplifying effect, habitual THC use could theoretically blunt part of MK-677's nocturnal GH benefit.

Practical Timing Guidance

Most MK-677 users dose at bedtime to align the GH pulse with natural nocturnal secretion. If cannabis is used the same evening, the THC-related REM suppression and possible alteration of slow-wave architecture may reduce the sleep quality benefit. CBD-dominant preparations without significant THC content do not appear to suppress REM and may be neutral or mildly beneficial for sleep latency based on limited clinical data [11].

Pharmacokinetic Interaction: CYP3A4

MK-677 is metabolized primarily by CYP3A4. CBD inhibits CYP3A4 in a dose-dependent manner. The FDA's guidance on drug interactions identifies CYP3A4 as a major pathway; co-administration with a CYP3A4 inhibitor can raise AUC of the substrate drug substantially [3].

Magnitude Estimate

CBD at recreational vapor/edible doses (10-30 mg) produces plasma CBD concentrations below the threshold for meaningful CYP3A4 inhibition in most adults. Pharmaceutical-grade oral CBD (Epidiolex) at therapeutic doses of 10-25 mg/kg/day does produce clinically significant CYP3A4 inhibition, as confirmed by interactions with clobazam and valproate in the key epilepsy trials [3]. For the typical recreational user, this interaction is low-magnitude. For patients prescribed Epidiolex alongside MK-677, a pharmacist review is mandatory.

THC Metabolic Pathway

THC is primarily metabolized by CYP2C9 and CYP3A4 to 11-OH-THC and then THC-COOH. It does not appear to be a clinically significant inhibitor of CYP3A4 at standard recreational doses. There is no well-characterized pharmacokinetic interaction between THC and MK-677 based on current data.

Special Populations

Users Running GH or IGF-1 Optimizing Protocols

Some athletes and longevity-focused users combine MK-677 with other peptides (e.g., CJC-1295, BPC-157) or anabolic agents. Adding cannabis to an already complex stack increases the number of overlapping metabolic variables. Glucose monitoring becomes more difficult to interpret when multiple agents simultaneously affect insulin signaling.

Women and Hormonal Considerations

MK-677 modestly raises prolactin in some users. THC also transiently raises prolactin levels via dopaminergic mechanisms [8]. Additive hyperprolactinemia is a theoretical concern for women on MK-677 who use cannabis frequently, though clinical thresholds for prolactin-related symptoms (galactorrhea, menstrual irregularity) require sustained, significantly elevated levels that are unlikely from either agent at standard doses.

Adolescents and Young Adults

The endocannabinoid system is not fully mature until approximately age 25 [6]. MK-677 is not approved for pediatric or adolescent use, and no safety data exist for the combination with cannabis in this age group. Both agents in individuals under 25 carry independent developmental risks; combining them is not supported by any existing evidence base.

What the Absence of RCT Data Actually Means

The clinical picture here is constructed from mechanistic reasoning and indirect evidence, not a head-to-head trial. A 2023 scoping review of growth hormone secretagogue drug interaction data identified zero registered trials evaluating any GHS compound alongside cannabis or cannabinoids, confirming the total absence of direct evidence [7].

The Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency notes that "the safety and efficacy of non-FDA-approved secretagogues have not been established in rigorous clinical trials" [12]. That advisory applies with even more force when a second unapproved or Schedule I substance is layered on top.

What Clinicians Are Saying

Dr. Nir Barzilai, a prominent longevity researcher at Albert Einstein College of Medicine and an investigator in IGF-1-related trials, has commented publicly that "any secretagogue use outside a monitored clinical setting introduces risks that are not fully characterized, particularly regarding metabolic endpoints." While this statement was not made specifically about cannabis co-use, it reflects the broader expert consensus that MK-677 warrants monitoring even in isolation.

Summary of the Interaction Matrix

| Interaction Domain | Direction | Magnitude | Evidence Quality | |---|---|---|---| | Appetite amplification | Additive | Moderate-High | Mechanistic + indirect | | Insulin resistance | Additive (heavy THC use) | Moderate | Animal + epidemiological | | CYP3A4 inhibition (CBD) | Increases MK-677 exposure | Low (recreational), Moderate (high-dose CBD) | In vitro + pharmaceutical trial | | REM suppression (THC) | Opposes MK-677 sleep benefit | Moderate | RCT on each agent separately | | Cardiovascular (THC tachycardia + fluid retention) | Additive cardiac work | Low-Moderate | Mechanistic | | Prolactin elevation | Possible additive | Low | Case reports |